The Global Health Body Issues Warning Over Acute Scarcity of Weight-Loss Jabs
Fewer than a tenth of patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, states the WHO as it issues its first advice on the drugs.
With more than one billion people worldwide now classified as obese, it is urging increased and just availability to GLP-1 medication.
According to projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The new guidance affirms that excess weight is a long-term condition that can be managed with comprehensive and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are major hurdles to broad availability to the treatments that can aid individuals in losing considerable body mass, explains the agency.
GLP-1 Therapy Supply Crisis
Even under the present most optimistic scenario, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – fewer than 10% of the global need, according to the WHO.
The recommendation urges governments and firms to expand availability, via strategies like patent sharing.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is due to expire in a number of countries in 2026.
The Way Obesity Jabs Function
The injections replicate a natural hormone to delay gastric emptying, suppress the appetite and enhance satiety so users consume fewer calories.
People usually begin shedding pounds in the initial weeks of beginning the weekly injections.
Studies indicates people may see weight return a year later of stopping the drug, when their normal hunger come back.
To be carrying excess weight increases your chance for experiencing diseases, like diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight impacts individuals in every country and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.
